[1]
|
Sung, H., Ferlay, J., Siegel, R.L., et al. (2021) Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: A Cancer Journal for Clinicians, 71, 209-249.
https://doi.org/10.3322/caac.21660
|
[2]
|
Tanner, M., Hollmen, M., Junttila, T.T., et al. (2005) Amplification of HER-2 in Gastric Carcinoma: Association with Topoisomerase IIalpha Gene Amplification, Intestinal Type, Poor Prog-nosis and Sensitivity to Trastuzumab. Annals of Oncology, 16, 273-278. https://doi.org/10.1093/annonc/mdi064
|
[3]
|
Hudis, C.A. (2007) Trastuzumab—Mechanism of Action and Use in Clinical Practice. The New England Journal of Medicine, 357, 39-51. https://doi.org/10.1056/NEJMra043186
|
[4]
|
Bang, Y.J., Van Cutsem, E., Feyereislova, A., et al. (2010) Trastuzumab in Combination with Chemotherapy versus Chemotherapy Alone for Treatment of HER2-Positive Ad-vanced Gastric or Gastro-Oesophageal Junction Cancer (ToGA): A Phase 3, Open-Label, Randomised Controlled Trial. The Lancet, 376, 687-697.
https://doi.org/10.1016/S0140-6736(10)61121-X
|
[5]
|
Joshi, S.S. and Badgwell, B.D. (2021) Current Treatment and Recent Progress in Gastric Cancer. CA: A Cancer Journal for Clinicians, 71, 264-279. https://doi.org/10.3322/caac.21657
|
[6]
|
Abrahao-Machado, L.F. and Scapulatempo-Neto, C. (2016) HER2 Testing in Gastric Cancer: An Update. World Journal of Gastroenterology, 22, 4619-4625. https://doi.org/10.3748/wjg.v22.i19.4619
|
[7]
|
中国抗癌协会胃癌专业委员会. 胃癌诊治难点中国专家共识(2020版) [J]. 中国实用外科杂志, 2020, 40(8): 869-904.
|
[8]
|
Kim, S.H., Kim, S.H., Kim, M.A., et al. (2015) CT Differentiation of Poorly-Differentiated Gastric Neuroendocrine Tumours from Well-Differentiated Neuroendocrine Tu-mours and Gastric Adenocarcinomas. European Radiology, 25, 1946-1957. https://doi.org/10.1007/s00330-015-3600-z
|
[9]
|
Ahadi, M., Moradi, A., Musavinejad, L., et al. (2020) The Ex-pression of p53, CD44, Ki-67, and HER-2/neu Markers in Gastric Cancer and Its Association with Histopathological In-dicators: A Retrospective Study. Asian Pacific Journal of Cancer Prevention, 21, 1607-1614. https://doi.org/10.31557/APJCP.2020.21.6.1607
|
[10]
|
Wang, N., Wang, X., Li, W., et al. (2020) Con-trast-Enhanced CT Parameters of Gastric Adenocarcinoma: Can Radiomic Features Be Surrogate Biomarkers for HER2 Over-Expression Status? Cancer Management and Research, 12, 1211-1219. https://doi.org/10.2147/CMAR.S230138
|
[11]
|
李玉珠, 李亚平, 李彦良. HER-2蛋白表达与多层螺旋CT胃癌征象相关性分析及应用[J]. 影像科学与光化学, 2021, 39(5): 684-688.
|
[12]
|
赵瑾, 陈海燕, 丁信法, 等. 胃癌MSCT表现和临床病理特征与HER2表达的相关性研究[J]. 实用肿瘤杂志, 2020, 35(3): 201-207.
|
[13]
|
潘圣宝, 雷振. 进展期胃癌多层螺旋CT表现与HER2表达的相关性[J]. 中国医学影像学杂志, 2019, 27(4): 282-285.
|
[14]
|
刘洋, 高剑波, 岳松伟, 等. CT强化率、灌注参数与胃癌病灶中HER2表达的关系[J]. 世界华人消化杂志, 2015, 23(3): 426-431.
|
[15]
|
Lee, J.S., Kim, S.H., Im, S.A., et al. (2017) Human Epidermal Growth Factor Receptor 2 Expres-sion in Unresectable Gastric Cancers: Relationship with CT Characteristics. Korean Journal of Radiology, 18, 809-820.
https://doi.org/10.3348/kjr.2017.18.5.809
|
[16]
|
郑红伟, 彭晓博, 郑凌云, 等. 胃癌CT征象与HER2基因表达的相关性研究[J]. 中国CT和MRI杂志, 2021, 19(1): 161-164.
|
[17]
|
Petralia, G., Preda, L., D’andrea, G., et al. (2010) CT Perfusion in Solid-Body Tumours. Part I: Technical Issues. La Radiologia Medica, 115, 843-857. https://doi.org/10.1007/s11547-010-0519-y
|
[18]
|
黄列彬, 龙晚生, 陈钦贤, 等. CT灌注成像对进展期胃癌HER2表达状态的评估价值[J]. 遵义医科大学学报, 2020, 43(5): 641-645.
|
[19]
|
李慧, 征锦, 叶靖. 低剂量CT灌注成像对胃癌分化程度评估及Her2、EGFR水平相关性研究[J]. 中华消化病与影像杂志(电子版), 2020, 10(6): 252-255.
|
[20]
|
张笑, 黄伟, 宋彬. 基于CT平扫图像的纹理分析区分胃癌HER2表达的可行性研究[J]. 中国普外基础与临床杂志, 2021, 28(9): 1221-1226.
|
[21]
|
Wang, Y., Yu, Y., Han, W., et al. (2021) CT Radiomics for Distinction of Human Epidermal Growth Factor Receptor 2 Negative Gastric Cancer. Academic Radiology, 28, e86-e92. https://doi.org/10.1016/j.acra.2020.02.018
|
[22]
|
Zhao, H., Li, W., Huang, W., et al. (2021) Dual-Energy CT-Based Nomogram for Decoding HER2 Status in Patients with Gastric Cancer. AJR. American Journal of Roentgenology, 216, 1539-1548. https://doi.org/10.2214/AJR.20.23528
|
[23]
|
Wang, S., Chen, Y., Zhang, H., et al. (2021) The Value of Predicting Human Epidermal Growth Factor Receptor 2 Status in Adenocarcinoma of the Esophagogastric Junction on CT-Based Radiomics Nomogram. Frontiers in Oncology, 11, Article ID: 707686. https://doi.org/10.3389/fonc.2021.707686
|
[24]
|
He, J., Shi, H., Zhou, Z., et al. (2015) Correlation between Appar-ent Diffusion Coefficients and HER2 Status in Gastric Cancers: Pilot Study. BMC Cancer, 15, Article No. 749. https://doi.org/10.1186/s12885-015-1726-7
|
[25]
|
Ji, C., Zhang, Q., Guan, W., et al. (2017) Role of Intravoxel In-coherent Motion MR Imaging in Preoperative Assessing HER2 Status of Gastric Cancers. Oncotarget, 8, 49293-49302. https://doi.org/10.18632/oncotarget.17570
|
[26]
|
王铮, 苏丹柯, 赖少侣, 等. 胃癌MRI非形态学表征与Her-2表达水平的相关性分析[J]. 临床放射学杂志, 2019, 38(2): 281-285.
|
[27]
|
王姣, 次旦旺久, 卢海燕, 等. 胃癌DWI ADC值与HER-2、CEA表达的相关性分析[J]. 现代肿瘤医学, 2020, 28(21): 3749-3752.
|
[28]
|
张霄, 曲金荣, 张宏凯, 等. 动态对比增强MRI定量参数直方图分析在胃癌HER2表达中的应用价值[J]. 放射学实践, 2021, 36(9): 1110-1115.
|
[29]
|
Erturk, S.A., Hasbek, Z. and Ozer, H. (2021) The Relationship between HER-2 Expression Levels and 18F-FDG PET/CT Parameters in Gastric Cancer. Molecular Imaging and Radionuclide Therapy, 30, 150-157.
https://doi.org/10.4274/mirt.galenos.2021.78055
|
[30]
|
Celli, R., Colunga, M., Patel, N., et al. (2016) Metabolic Signature on 18F-FDG PET/CT, HER2 Status, and Survival in Gastric Adenocarcinomas. Journal of Nuclear Medicine Technology, 44, 234-238.
https://doi.org/10.2967/jnmt.116.181479
|
[31]
|
弭丽丽, 殷飞, 雷连会, 等. 18F-FDG PET/CT相关参数与胃癌患者HER2表达状态的相关性研究[J]. 中国肿瘤临床, 2021, 48(6): 301-305.
|
[32]
|
Chen, R., Zhou, X., Liu, J., et al. (2016) Relationship between 18F-FDG PET/CT Findings and HER2 Expression in Gastric Cancer. The Journal of Nu-clear Medicine, 57, 1040-1044. https://doi.org/10.2967/jnumed.115.171165
|
[33]
|
Park, J.S., Lee, N., Beom, S.H., et al. (2018) The Prognostic Value of Volume-Based Parameters Using 18F-FDG PET/CT in Gastric Cancer According to HER2 Status. Gastric Cancer, 21, 213-224.
https://doi.org/10.1007/s10120-017-0739-0
|
[34]
|
Bai, L., Guo, C.H., Zhao, Y., et al. (2017) SUVmax of 18F-FDG PET/CT Correlates to Expression of Major Chemotherapy-Related Tumor Markers and Serum Tumor Markers in Gastric Adenocarcinoma Patients. Oncology Reports, 37, 3433-3440. https://doi.org/10.3892/or.2017.5631
|